Linker Information
General Information of This Linker
| Linker ID |
LIN0YQOGM
|
|||||
|---|---|---|---|---|---|---|
| Linker Name |
A cleavable ester linker
|
|||||
| Linker Type |
Unclear
|
|||||
| Antibody-Linker Relation |
Cleavable
|
|||||
| Structure |
|
|||||
| Formula |
C71H119N17O31
|
|||||
| Isosmiles |
[H][C@@]12CCC3=C(CC[C@@]1([C@@H]2COC(NCCOCCOCCNC(CCC(NCC(NCCOCCC(NCCC(NCC(NCC(NCC(NCC(N[C@H](C(NCCOCCOCCOCCOCCOCCOCCOCCOC)=O)COC(NCCC(N[C@H](C(O)=O)CCC(N[C@@H](C)C(O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)[H])N=NN3
|
|||||
| InChI |
InChI=1S/C71H119N17O31/c1-48(68(101)102)83-60(93)8-7-54(69(103)104)84-61(94)12-15-76-70(105)119-47-55(67(100)75-18-23-110-29-30-113-33-34-115-37-38-117-40-39-116-36-35-114-32-31-112-26-25-107-2)85-66(99)45-82-65(98)44-81-64(97)43-80-63(96)42-79-58(91)11-14-72-59(92)13-20-108-21-17-74-62(95)41-78-57(90)10-9-56(89)73-16-22-109-27-28-111-24-19-77-71(106)118-46-51-49-3-5-52-53(87-88-86-52)6-4-50(49)51/h48-51,54-55H,3-47H2,1-2H3,(H,72,92)(H,73,89)(H,74,95)(H,75,100)(H,76,105)(H,77,106)(H,78,90)(H,79,91)(H,80,96)(H,81,97)(H,82,98)(H,83,93)(H,84,94)(H,85,99)(H,101,102)(H,103,104)(H,86,87,88)/t48-,49-,50+,51-,54-,55-/m0/s1
|
|||||
| InChIKey |
NOGWFLAKIOHPHB-ZRWVUPPZSA-N
|
|||||
| Pharmaceutical Properties |
Molecule Weight
|
1706.821
|
Polar area
|
643.56
|
||
|
Complexity
|
3044.349259
|
xlogp Value
|
-7.7695
|
|||
|
Heavy Count
|
119
|
Rot Bonds
|
71
|
|||
|
Hbond acc
|
31
|
Hbond Donor
|
17
|
|||
Each Antibody-drug Conjugate Related to This Linker
Full Information of The Activity Data of The ADC(s) Related to This Linker
Emiltatug ledadotin [Phase 1]
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Patients Enrolled |
Eligible patients (ECOG 0-1) have recurrent/advanced solid tumors (measurable per RECIST 1.1) and available tumor tissue. Key exclusions: prior auristatin-ADC treatment, untreated CNS metastases, active liver disease (cirrhosis/varices), uncontrolled systemic illness, or recent anticancer therapy/surgery (within specified washout periods). Brain MRI is required for TNBC or symptomatic/metastatic CNS history.
Click to Show/Hide
|
||||
| Administration Dosage |
XMT-1660 will be administered through a vein in your arm or port catheter (intravenously)
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT05377996 | Clinical Status | PHASE1 | ||
| Clinical Description |
A Phase 1, First-in-human, Dose Escalation and Expansion, Multicenter Study of XMT-1660 in Participants With Solid Tumors
|
||||
| Primary Endpoint |
The Phase 1 study evaluates DLTs within the first treatment cycle (17 months) to establish MTD/RP2D for XMT-1660, with safety/tolerability assessed via AEs over 3 years. Phase 2 expansion measures ORR per RECIST 1.1 (investigator-assessed CR/PR rates).
|
||||
| Other Endpoint |
Secondary endpoints include ORR (dose escalation), DOR (time to progression/death), and comprehensive PK analysis (Tmax, Cmax, AUC, clearance, half-life, volume of distribution, Ctrough) over 3 years. Immunogenicity (ADA/nAb development) is monitored throughout both phases.
|
||||